On September 21, Sunflower (300111.SZ) announced a significant acquisition plan. The company intends to acquire 100% equity of Zhangzhou Xipu Material Technology and 40% equity of Zhejiang Beide Pharmaceutical through a combination of share issuance and cash payment, along with raising supporting funds. Following this news, the company’s shares will resume trading on September 22.
Xipu Material specializes in the R&D, manufacturing, and sales of high-end semiconductor materials, including ultra-high purity electronic specialty gases, silicon-based precursors, and metal-based precursors, which are widely used in key semiconductor manufacturing processes. Beide Pharmaceutical, a subsidiary of Sunflower, focuses on the R&D, production, and sales of drugs for anti-infective, cardiovascular, and digestive system treatments.
Sunflower stated that this acquisition aims to expand its business scope and enhance its competitiveness in the high-end semiconductor materials market. The advanced technology and diverse product portfolio of Xipu Material will support Sunflower’s strategic positioning within the semiconductor industry chain. Additionally, increasing its stake in Beide Pharmaceutical will further strengthen the company’s presence in the pharmaceutical sector.
Amid rapid growth in the semiconductor industry and strong market demand for high-end semiconductor materials, this move represents a key step in Sunflower’s strategy to diversify and enhance its core competitiveness. The integration of Xipu Material is expected to create new growth opportunities, while the increased ownership in Beide Pharmaceutical will improve overall profitability and market influence.
ICgoodFind : Sunflower’s cross-sector acquisition of a high-end semiconductor materials company marks a significant strategic expansion, presenting new opportunities and challenges for future growth.
